Cargando…

Safety and effectiveness of mepolizumab therapy in remission induction therapy for eosinophilic granulomatosis with polyangiitis: a retrospective study

OBJECTIVES: To investigate the safety and effectiveness of mepolizumab (MPZ), an anti-interleukin-5 antibody, as remission induction therapy for severe eosinophilic granulomatosis with polyangiitis (EGPA). METHODS: The clinical courses of patients with severe EGPA over 6 months were retrospectively...

Descripción completa

Detalles Bibliográficos
Autores principales:	Ueno, Masanobu, Miyagawa, Ippei, Aritomi, Takafumi, Kimura, Koichi, Iwata, Shigeru, Hanami, Kentaro, Fukuyo, Syunsuke, Kubo, Satoshi, Miyazaki, Yusuke, Nakayamada, Shingo, Tanaka, Yoshiya
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2022
Materias:	Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9241238/ https://www.ncbi.nlm.nih.gov/pubmed/35768825 http://dx.doi.org/10.1186/s13075-022-02845-3

Ejemplares similares

Effectiveness and safety of mepolizumab in combination with corticosteroids in patients with eosinophilic granulomatosis with polyangiitis
por: Ueno, Masanobu, et al.
Publicado: (2021)

Mepolizumab therapy improves endomyocarditis in seropositive eosinophilic granulomatosis with polyangiitis
por: Wang, Chrong-Reen, et al.
Publicado: (2022)

Safety and Efficacy of Mepolizumab in Patients with Eosinophilic Granulomatosis with Polyangiitis
por: Pradhan, Ravi Ranjan, et al.
Publicado: (2019)

Remission of Granulomatosis with Polyangiitis Only After Resection of a Pulmonary Nodule
por: Kanda, Ryuichiro, et al.
Publicado: (2022)

Pharmacogenetic investigation of efficacy response to mepolizumab in eosinophilic granulomatosis with polyangiitis
por: Condreay, Lynn D., et al.
Publicado: (2020)

Mepolizumab therapy in a pediatric patient with eosinophilic granulomatosis with polyangiitis associated with refractory myocarditis
por: Ulu, Kadir, et al.
Publicado: (2022)

Eosinophilic granulomatosis with polyangiitis exhibits T cell activation and IgG4 immune response in the tissue; comparison with IgG4-related disease
por: Kubo, Satoshi, et al.
Publicado: (2022)

Efficacy and safety of guselkumab and adalimumab for pustulotic arthro-osteitis and their impact on peripheral blood immunophenotypes
por: Ueno, Masanobu, et al.
Publicado: (2022)

Correction: Efficacy and safety of guselkumab and adalimumab for pustulotic arthro-osteitis and their impact on peripheral blood immunophenotypes
por: Ueno, Masanobu, et al.
Publicado: (2023)

Generation-Dependent Retention Rates and Reasons for Discontinuation of Molecular Targeted Therapies in Patients with Rheumatoid Arthritis: From FIRST Registry
por: Kubo, Satoshi, et al.
Publicado: (2023)

Concurrent Use of Mepolizumab and Rituximab for Eosinophilic Granulomatosis With Polyangiitis and Multisystem Involvement
por: Afiari, Agura, et al.
Publicado: (2020)

Mepolizumab for Eosinophilic Granulomatosis With Polyangiitis: A European Multicenter Observational Study
por: Bettiol, Alessandra, et al.
Publicado: (2021)

Successful Treatment With Mepolizumab for Eosinophilic Granulomatosis With Polyangiitis: A Case Report
por: Toscano Peña, Andrés, et al.
Publicado: (2023)

A Case of Effective Mepolizumab Induction Therapy for Severe Eosinophilic Granulomatosis with Polyangiitis Diagnosed by Eosinophilic Cholecystitis and Interstitial Nephritis
por: Hattori, Keita, et al.
Publicado: (2021)

Low-Dose Mepolizumab Effectiveness in Patients Suffering From Eosinophilic Granulomatosis With Polyangiitis
por: Vultaggio, Alessandra, et al.
Publicado: (2020)

A Pediatric Case of Relapsing Eosinophilic Granulomatosis with Polyangiitis Successfully Treated with Mepolizumab
por: Nara, Mizuho, et al.
Publicado: (2019)

Successful treatment with benralizumab in a patient with eosinophilic granulomatosis with polyangiitis refractory to mepolizumab
por: Menzella, Francesco, et al.
Publicado: (2021)

Successful Treatment with Mepolizumab for Coronary Spastic Angina Associated with Eosinophilic Granulomatosis with Polyangiitis
por: Takigawa, Yuki, et al.
Publicado: (2023)

Mepolizumab as the first targeted treatment for eosinophilic granulomatosis with polyangiitis: a review of current evidence and potential place in therapy
por: Faverio, Paola, et al.
Publicado: (2018)

Anti-neutrophil Cytoplasmic Antibody-negative Eosinophilic Granulomatosis with Polyangiitis Complicated with Peripheral Neuropathy that Underwent Remission Induction with Mepolizumab Monotherapy
por: Nishihara, Masahiro, et al.
Publicado: (2023)

Clinical Benefit of Mepolizumab in Eosinophilic Granulomatosis With Polyangiitis for Patients With and Without a Vasculitic Phenotype
por: Terrier, Benjamin, et al.
Publicado: (2023)

Characteristics and Disease Burden of Patients With Eosinophilic Granulomatosis With Polyangiitis Initiating Mepolizumab in the United States
por: Silver, Jared, et al.
Publicado: (2023)

Real-world characteristics of “super-responders” to mepolizumab and benralizumab in severe eosinophilic asthma and eosinophilic granulomatosis with polyangiitis
por: Portacci, Andrea, et al.
Publicado: (2023)

Long-term mepolizumab treatment reduces relapse rates in super-responders with eosinophilic granulomatosis with polyangiitis
por: Masumoto, Nami, et al.
Publicado: (2023)

Comparative study of corticosteroid monotherapy, and TNF inhibitors with or without corticosteroid in patients with refractory entero-Behcet’s disease
por: Miyagawa, Ippei, et al.
Publicado: (2019)

Eosinophilic Granulomatosis with Polyangiitis
por: Shukla, Ratnakar, et al.
Publicado: (2022)

Effective treatment with mepolizumab in a patient with severe eosinophilic granulomatosis with polyangiitis complicated with small intestine perforation
por: Sato, Mari, et al.
Publicado: (2023)

Serum TNFα levels at 24 h after certolizumab pegol predict effectiveness at week 12 in patients with rheumatoid arthritis from TSUBAME study
por: Miyazaki, Yusuke, et al.
Publicado: (2021)

Switching from omalizumab to mepolizumab therapy improved extra‐pulmonary abdominal and cutaneous vasculitis symptoms in a patient with eosinophilic granulomatosis with polyangiitis
por: Chen, Yu‐Hsuan, et al.
Publicado: (2021)

COVID-19 and eosinophilic granulomatosis with polyangiitis or COVID-19 mimicking eosinophilic granulomatosis with polyangiitis?
por: Özdemir, Bahar, et al.
Publicado: (2021)

The Efficacy of Mycophenolate Mofetil in Remission Maintenance Therapy for Microscopic Polyangiitis and Granulomatosis with Polyangiitis
por: Pyo, Jung Yoon, et al.
Publicado: (2021)

Eosinophilic granulomatosis with polyangiitis after treatment with dupilumab
por: Yamazaki, Kai, et al.
Publicado: (2022)

Improvement of peripheral neuropathy in a patient with antineutrophil cytoplasmic antibody-negative eosinophilic granulomatosis with polyangiitis by additional mepolizumab
por: Kai, Yoshiro, et al.
Publicado: (2022)

Eosinophilic Granulomatosis with Polyangiitis: An Overview
por: Gioffredi, Andrea, et al.
Publicado: (2014)

Prevasculitic Eosinophilic Granulomatosis With Polyangiitis
por: Burtson, Kathryn M, et al.
Publicado: (2021)

Eosinophilic Variant of Granulomatosis With Polyangiitis
por: Fernandes, Rui L, et al.
Publicado: (2023)

Correction to: COVID-19 and eosinophilic granulomatosis with polyangiitis or COVID-19 mimicking eosinophilic granulomatosis with polyangiitis?
por: Özdemir, Bahar, et al.
Publicado: (2021)

Benralizumab monotherapy was insufficient to induce remission in patients with active eosinophilic granulomatosis with polyangiitis
por: Matsuno, Osamu, et al.
Publicado: (2022)

Eosinophilic Cholecystitis Associated with Eosinophilic Granulomatosis with Polyangiitis
por: Ito, Hiroyuki, et al.
Publicado: (2020)

High-dose intravenous immunoglobulin therapy for eosinophilic granulomatosis with polyangiitis
por: Tsurikisawa, Naomi, et al.
Publicado: (2014)

Cannot write session to /tmp/vufind_sessions/sess_fceb3908j1s9ua5enqes2r3oim